Pre-market Hot Trades in US Stocks
Greenlane is down 13.38% in pre-market trading. Based on recent news,
<ol>
<li>
On March 31, Greenlane faced the risk of delisting from Nasdaq and plans to appeal the hearing. This news raised market concerns, leading to a significant drop in stock price.
</li>
<li>
On April 1, Greenlane released its Q4 2025 and full-year financial report, showing a decrease in revenue and a net loss widening to $69.6 million. The poor financial performance further undermined investor confidence.
</li>
<li>
On April 1, analyst reports indicated that Greenlane's technical performance is weak, with the stock price below key moving averages and a negative MACD indicator, resulting in an overall technical signal to sell. The market reacted strongly to the financial performance and delisting risk.
</li>
</ol>
bioAffinity Tech is up 10.70% in pre-market trading, with no significant news recently. Trading is active, and there is a clear flow of funds. Considering sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation.
Top Gainers in Pre-market US Stocks
Cyclerion is up 160.63% in pre-market trading. Based on recent key news:
<ol>
<li>
On April 1, Cyclerion Therapeutics announced a merger with Korsana Biosciences, shifting focus to Alzheimer's disease treatment. Post-merger, the company will receive $380 million in private financing led by Fairmount and Venrock, sufficient to support operations until 2029. This news drove the stock price up 37.4% in pre-market trading. Source: Reuters
</li>
<li>
On April 1, following the announcement of the merger agreement, Cyclerion shareholders will hold approximately 1.5% of the new company, which will trade on Nasdaq under the ticker &#34;KRSA.&#34; This move further boosted market confidence, driving the stock price higher. Source: Reuters
</li>
<li>
On April 1, Korsana's experimental drug KRSA-028 is planned for early testing in healthy volunteers by mid-2027, with preliminary patient data expected to be released later that year. This drug aims to slow the progression of Alzheimer's disease by targeting toxic brain proteins, enhancing investor expectations for future growth. Source: Reuters The biotechnology industry is focused on Alzheimer's disease treatment.
</li>
</ol>
Binah Capital is up 60.59% in pre-market trading. Based on recent key news:
<ol>
<li>
On March 31, Binah Capital released its Q4 2025 and full-year financial report, showing strong financial performance, which significantly boosted the stock price. According to the company's announcement, both revenue and profit exceeded market expectations, enhancing investor confidence.
</li>
<li>
On March 31, Binah Capital disclosed its financial data in documents submitted to the SEC, further confirming the robustness of its performance. The transparency of this information has improved market expectations for its future growth
On April 1st, the market reacted strongly to Binah Capital's positive financial report, leading to a significant increase in stock prices during pre-market trading. Investor optimism regarding its future profitability drove a notable rise in stock prices. The market's positive response to the financial report resulted in a clear influx of capital.
</li>
</ol>
Defi Tech rose 35.38% in pre-market trading. Based on recent key news:
<ol>
<li>
On April 1st, DeFi Technologies announced its preliminary unaudited financial performance for 2025, with revenue reaching $99.1 million and net profit of $62.7 million, both hitting record highs. Annual revenue grew by 215% year-on-year, turning from a net loss in 2024 to profitability. This news propelled the stock price to rise 37.06% after hours. Source: Company press release
</li>
<li>
On March 31st, DeFi Technologies announced the appointment of Jacob Lindberg as Chief Revenue Officer of Valour, responsible for leading the expansion in the Nordic and European markets. This move is seen as a signal of the company's strategic growth in these regions, boosting market confidence. Source: Company news
</li>
<li>
On March 30th, DeFi Technologies announced Jacob Lindberg's appointment, further emphasizing the company's expansion plans for its digital asset ETP platform, driving the stock price up. Source: Company news The digital asset industry is growing rapidly, attracting significant market attention
</li>
</ol>

GNLN

BIAF

Greenlane pre-market down 13.38%; bioAffinity Tech pre-market up 10.70%; Cyclerion Therapeutics pre-market up 160.63%; Binah Capital pre-market up 60.59%; Defi Tech pre-market up 35.38%

Pre-market hot trades in US stocks: Greenlane pre-market down 13.38%; bioAffinity Tech pre-market up 10.70%